Primary Peritoneal Cancer Clinical Trials in Georgia

Georgia's Online Cancer Information Center


back

Primary Peritoneal Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Primary Peritoneal Cancer
Cancer Type = Primary Peritoneal Cancer
NCI ID Cancer Type Trial Name
There are currently 21 active Primary Peritoneal Cancer clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT07318558
Protocol IDs
2870-021
NCI-2026-02084
2023
2023-508047-40-00
ENGOT-ov85
GOG-3102
jRCT2031250647
MK-2870-021
U1111-1297-5158
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
2.
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Cancer Type
Cancer-Related Syndrome, Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Sarcoma
NCT ID
NCT06823167
Protocol IDs
IM-1021-101
NCI-2025-03470
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
3.
A Study Combining the Peposertib (M3814) Pill with Standard Chemotherapy in Patients with Ovarian Cancer with an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT04092270
Protocol IDs
10324
10324
NCI-2019-06123
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
4.
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT06072781
Protocol IDs
VS-6766-301
NCI-2024-00300
ENGOT-ov81
GOG-3097
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
5.
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Cancer Type
Gynecologic Cancers, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05128825
Protocol IDs
ZN-c3-005
NCI-2022-03875
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
6.
NCORP Trial
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT07023627
Protocol IDs
INCB123667-203
GOG-3129/INCB123667-203 ( Other Identifier ) (OTHE
2025-521513-14-00 ( Registry Identifier ) (REGISTR
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
7.
A Study of Sovilnesib in Subjects with Ovarian Cancer
Cancer Type
Gynecologic Cancers, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT06084416
Protocol IDs
SOVI-2302
NCI-2024-02290
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
8.
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT06824467
Protocol IDs
2870-022
NCI-2025-03436
2023-508015-23
2023-508015-23-00
ENGOT-ov84
GOG-3103
jRCT2031240722
MK-2870-022
TroFuse-022
U1111-1297-4489
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Winship Cancer Institute of Emory University
Atlanta
9.
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Cancer Type
Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Solid Tumor
NCT ID
NCT04300556
Protocol IDs
MORAb-202-G000-201
NCI-2020-06147
2019-003600-12
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
10.
NCORP Trial
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT07213804
Protocol IDs
27727
NCI-2026-00146
2025-522255-25-00
APGOT-OV17
ENGOT-ov97/GINECO-NOGGO
GOG-3133
J5E-MC-JZXB
Treatment Sites (2)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Winship Cancer Institute of Emory University
Atlanta
11.
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT05281471
Protocol IDs
Olvi-Vec-022
NCI-2023-04441
GOG-3076
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
12.
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05659381
Protocol IDs
GOG-3068
NCI-2023-08813
217908
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
13.
NCORP Trial
Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04095364
Protocol IDs
NRG-GY019
NRG-GY019
NCI-2019-01460
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
14.
Message-Based Communication Outreach Intervention in Engaging Ovarian Cancer Survivors and Relatives to Consider Genetic Screening Services
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04927013
Protocol IDs
RSPH4984-20
NCI-2020-02281
STUDY00000224
15.
NCORP Trial
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05445778
Protocol IDs
IMGN853-0421
NCI-2023-00369
16.
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT06276491
Protocol IDs
XmAb541-01
NCI-2024-03773
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
17.
NCORP Trial
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05870748
Protocol IDs
STRO-002-GM3
NCI-2023-04597
APGOT-OV9
ENGOT-OV79
GEICO-134-O
GOG-3086
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
18.
NCORP Trial
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05257408
Protocol IDs
CORT125134-556
NCI-2022-07960
GOG-3073
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
19.
Study of INCB123667 in Subjects With Advanced Solid Tumors
Cancer Type
Esophogeal Cancer, Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Stomach/ Gastric Cancer
NCT ID
NCT05238922
Protocol IDs
INCB 123667-101
NCI-2022-03370
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
20.
Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT05564377
Protocol IDs
EAY191
EAY191
NCI-2022-06842
21.
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05276973
Protocol IDs
NRG-GY027
NRG-GY027
NCI-2022-01930
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Find Cancer Care

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

 

Georgia CORE reduces the burden of cancer in our state through research, education, and advocacy.